[Adverse reactions to L-asparaginase in children with acute lymphatic leukemia].

نویسندگان

  • Mónica Kyonen L
  • Isabel Folatre B
  • Paolina Zolezzi R
  • Viviana Badilla M
  • Francisco Marín H
چکیده

BACKGROUND The low notification of Adverse Drug Reactions (ADR) underscores the need for pharmacological surveillance systems that allow their detection, evaluation, prevention and registry especially in patients receiving multiple medications. AIM To communicate the ADR observed with the use E coli asparaginase (E coli ASP) in children with Acute Lymphatic Leukemia (ALL). PATIENTS AND METHODS Cross-sectional study of clinical records of all the patients aged less than 15 years with ALL (n =52) and treated between January 1996 and April 2000. The suspicion of ADR to E coli ASP was evaluated using the Karch and Lasagna algorithm. Probable and definitive cases of ADR to E coli ASP were subjected to a protocol of clinical and epidemiological data. The risk factors associated to ADR to E coli ASP, were also determined. RESULTS Fifty children aged 1 to 13 years (33 men) were studied. In 20 (40%), an ADR to E coli ASP, was suspected. After the use of the algorithm, the ADR was considered definite in two patients, probable in 17 and possible in one. The registered clinical events were urticaria in 17, anaphylactic shock in four, transient alterations of hepatic functions test in seven and hypofibrinogenemia in four. The test of cutaneous sensitivity to the administration of E coli ASP, performed prior to the administration of the drug, were positive in nine of the 20 children with adverse reactions. No children died. CONCLUSIONS The application of the Karch anbd Lasagna algorithm, allowed us to objectively classify suspected cases of ADR by E coli ASP.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Brain MRI Findings in Children with Acute Lymphoblastic Leukemia

Background: Patients with leukemia are facing more complications in order to achieve longer survival. We aimed to evaluate the frequency of central nervous system abnormalities (CNS) on MRI of children with acute lymphoblastic leukemia (ALL). Methods: Sixty-six children with diagnosis of ALL aged 2-18 years were recruited. Non-contrast sequences of brain MRI in addition to diffusion weighted i...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial

The pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant Escherichia coli–asparaginase preparation was compared with Asparaginase medac. Thirty-two children with acute lymphoblastic leukemia were randomized to receive one of both agents at a dose of 5000 U/m2 every 3 days, for a total of 8 doses during induction treatment. The serum activity-time profile after the first...

متن کامل

Reactions related to asparaginase infusion in a 10-year retrospective cohort

INTRODUCTION Although it is an essential component of the treatment of acute lymphoid leukemia in children, asparaginase causes adverse reactions that sometimes make it impossible to use it fully. Hypersensitivity reactions are the most frequent and may lead to early discontinuation of treatment. The present study aimed to investigate suspicions of adverse reactions during the infusion of aspar...

متن کامل

Bioinformatic Analysis of L-Asparaginase II from Citrobacter Freundii 1101, Erwinia Chrysanthemi DSM 4610, E. coli BL21 and Klebsiella Pneumoniae ATCC 10031

Backgroung and Aims: L-Asparaginase II is a cornerstone of treatment protocols for acute lymphoblastic leukemia. Only asparaginase II obtained from E. coli K12 and Erwinia chrysanthemi have been used in human as therapeutic drug. The therapeutic effects of asparaginase II from E. coli K12 and Erwinia chrysanthemi is accompanied by side effects. It is desirable to search for other asparaginase I...

متن کامل

Response to highly purified L-asparaginase during therapy of acute leukemia.

Seven of nineteen patients with acute lymphatic leukemia and eight of eighteen patients with acute granulocytic leukemia received L-asparaginase according to a daily dosage schedule of 2,000 IU or more per kg for twenty-one days or more. Six of the seven acute lymphatic leukemia patients and four of the eight acute granulocytic leukemia patients underwent a complete bone marrow remission. In co...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Revista medica de Chile

دوره 134 12  شماره 

صفحات  -

تاریخ انتشار 2006